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Abstract
Background: Heart failure (HF) is characterized by high rates of readmission after hospitalization, and readmission is
a major contributor to healthcare costs. The transitional care model has proven efficacy in reducing the readmission
rate and economic outcomes, and increasing satisfaction with care. However, the effectiveness of the transitional
care model has not been evaluated in patients with end-stage HF. This study was designed to compare the
customary hospital-based care and a comprehensive transitional care model, namely the Home-based Palliative HF
Program (HPHP), in terms of readmission rate, quality of life, and satisfaction with care among end-stage HF
patients under palliative care.
Methods/design: This is a randomized controlled trial taking place in hospitals in Hong Kong. We have been
recruiting patients with end-stage HF who are identified as appropriate for palliative care during hospitalization, on
referral by their physicians. A set of questionnaires is collected from each participant upon discharge. Participants
are randomized to receive usual care (customary hospital-based care) or the intervention (HPHP). The HPHP will be
implemented for up to 12 months. Outcome measures will be performed at 1, 3, 6, and 12 months post-discharge.
The primary outcome of this study is quality of life measured by the Chronic Heart Failure Questionnaire - Chinese
version; secondary outcomes include readmission rate, symptom intensity, functional status, and satisfaction with
care.
Discussion: This study is original and will provide important information for service development in the area of
palliative care. The introduction of palliative care to end-stage organ failure patients is new and has received
increasing attention worldwide in the last decade. This study adopts the randomized controlled trial, a vigorous
research design, to establish scientific evidence in exploring the best model for end-stage HF patients receiving
palliative care.
Trial registration: This trial was registered as NCT02086305 on 7 March 2014 in the United States Clinical Trials
Registration, and in the Clinical Trials Registry, Hong Kong University with the trial number UW12202.
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Background
Heart failure (HF) is a global health issue affecting more
than 5 million people in the United States (US) [1] and 14
million Europeans [2]. In Hong Kong, the overall HF ratio
per 1,000 people is 0.7, resulting in a total of over 5,000
cases; the new:old case ratio is 2.8:1 [3]. Heart failure is the
leading cause of death in the US, accounting for 31.4 % of
all deaths and followed by cancer and stroke [4]. In Hong
Kong, cancer is still the leading cause of death (30.6 %), but
heart disease was ranked second (15.5 %) among the 42,705
deaths in 2009 [5]. The management of HF in recent years
has improved, but the mortality rate remains high, with a
reported 40 % death rate within the first year after diagnosis
[6, 7] and 75 % at five years [8]. Patients with heart failure
tend to need more emergency room visits, repeated hos-
pital admissions, and longer lengths of stay [1]. In Hong
Kong, around 25–50 % of HF patients are readmitted
within 6 months of discharge [9]. The repeated use of ser-
vices results in increased healthcare expenditures [10, 11],
costing US$30 billion a year in the US [1] and GBP 905
million in the United Kingdom [8].
The prognosis for patients with HF is poor, and vari-
ous burdens become prominent when HF progresses to
the end stage. End-stage heart failure is resistant to
medical therapy [1], and this group of patients experi-
ences a marked reduction in health-related quality of
life [6, 12], encountering health problems encompass-
ing physical, psychological, social, and spiritual aspects.
Topping the list of physical symptoms are fatigue, dys-
pnea, and edema [6, 12, 13]. Other reported symptoms
include decreased appetite, cough, dry mouth, and pain
[6, 12]. With their progressive decline in functional
status, these patients often have increasing difficulty
dealing with daily activities [14, 15]. Psychologically,
some patients with HF live in the shadow of fear [16],
experiencing emotional turbulence [17] and feeling
frustrated with their sense of personal failure [18]. Pa-
tients show symptoms of insomnia, worry, sadness, and
irritability [6, 12]. Socially, patients with HF feel iso-
lated and lonely [14, 19–21], often relying on others for
daily living assistance and thus regarding themselves as
a burden to their carers [19]. These patients also face
spiritual issues, such as questioning the meaning of liv-
ing with severe HF as they experience strong feelings of
uncertainty and hopelessness [20]. In fact, patients
understand that their condition could change rapidly,
including a sudden decline resulting in death [20, 22].
Apart from the symptom burden, heart failure also im-
poses a financial burden on the healthcare system, par-
ticularly in the form of hospital readmission [23, 24].
Heart failure is a leading cause of hospitalization, and a
systematic review confirmed that about 25 % of patients
hospitalized with HF are readmitted within 30 days
[23]. Reasons for hospital readmission were worsening
of symptoms, unavoidable progression of illness, dis-
tressing psychosocial issues, inadequate self-care adher-
ence, and lack of knowledge on how to seek help from
the healthcare provider [24, 25]. Therefore, it is essen-
tial to address end-stage HF patients’ physical, psycho-
logical, and spiritual needs in order to facilitate a better
hospital-to-home transition for them.
Patients with heart failure suffer from a number of
symptoms that profoundly impact their quality of life
(QoL) towards the end of life [1, 26]. They share similar
symptoms with patients who have cancer, including
breathlessness, fatigue, and edema [27–29]. QoL con-
cerns are also shared by cancer and non-cancer patients,
both of whom may benefit from a palliative approach to
their care [30, 31]. Traditional medical practice tends to
focus almost exclusively on curing illness and prolonging
life while treating advanced illnesses, rather than on im-
proving QoL and relieving suffering [32]. Contemporary
trends in the treatment of heart failure advocate the in-
tegration of palliative care into comprehensive heart fail-
ure management [33, 34]. Regarding the extensive
healthcare concerns raised during end-stage HF, recent
literature and guidelines indicate that the provision of
palliative care (PC) for end-stage HF patients is import-
ant. The American College of Cardiology and American
Heart Association Guidelines [35], the Heart Failure
Association of the European Society for Cardiology [36],
the Canadian Cardiovascular Society [37], and the Hong
Kong College of Physicians [38] all state that a palliative
approach to care for patients with end-stage HF should
be adopted.
Palliative care has a long history among patients with
cancer, and the evidence in palliative care research is sub-
stantial [39]. In recent years, although it has become clear
that palliative care can also benefit non-cancer patients, a
systematic review looking at the effectiveness of special-
ized palliative care concluded that evidence of the benefits
of this kind of care is sparse. Some authors have recom-
mended carefully planned trials using a standardized pal-
liative care intervention for terminally ill patients [40].
Specialized intervention [41] and coordination of care for
patients with end-stage HF is needed to help reduce the
risk of care fragmentation and to improve communication
when many health professionals are involved [36].
Therefore, we designed the present study aiming to
compare the effects of customary hospital-based care
and an interventional Home-based Palliative HF Pro-
gram (HPHP). Our objective is to examine the effect of
the HPHP on hospital readmission rate, quality of life,
functional status, symptom intensity, and satisfaction
with care. The key outcome of this study is the hospital
readmission rate, and the primary endpoint is 4 weeks
post-discharge. The hypothesis is that patients with end-
stage heart failure (ESHF) receiving the HPHP will have
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a lower hospital readmission rate than those receiving
customary hospital-based care at 4 weeks post-discharge.
Methods/design
Overview of study design
This is a two-group, single-blinded randomized con-
trolled trial. Participants are randomly allocated to two
groups: the customary hospital-based (control) group
and the HPHP (intervention) group. Eligible participants
will be recruited from three regional hospitals in Hong
Kong. The Standard Protocol Items: Recommendations
for Interventional Trials (SPIRIT) guidelines for the trial
are presented in Additional file 1.
Preparatory phase
The preparatory phase includes the development of
evidenced-based intervention protocols (6 months) and
a training program for service providers (6 months).
Trial phase
This study (that is, the baseline assessment of subjects
and intervention implementation for up to 12 months)
will take 12 months. Intervention effects will be mea-
sured at 1 month, 3 months, 6 months, and 12 months
and compared with the baseline measurements, as well
as between the HPHP and control groups (Fig. 1).
Conceptual framework
Studies have shown that supportive care programs using a
case management approach can reduce readmission rates
[42] and enhance quality of life [43]. Results from analyz-
ing 96 sets of case notes of home visits to hospice patients
showed that pain and edema can be quite well managed
through palliative home care services, but breathlessness
less so. Patients also experienced a number of social and
psychological issues, such as role change, guilt, and anger,
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Fig. 1 Flowchart for transition palliative care trial
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and palliative care proved helpful in reducing the intensity
of these symptoms [29].
This intervention introduces a comprehensive Home-
based Palliative HF Program (HPHP) to post-discharge pa-
tients with ESHF. The HPHP is built on two main
conceptual guides: the recommended six principles for pal-
liative HF care [44] and the four-Cs transitional care model.
The six principles are as follows: 1) there is case manage-
ment with coordination of care, communication and peri-
odic review of treatment goals, and a symptom control
plan with patient and family; 2) there are opportunities to
discuss end-of-life issues; 3) a multidisciplinary approach is
adopted; 4) there is a need for staff development, including
the art of communication, for cardiovascular and palliative
care; 5) topics for discussion of end-of-life issues include
advanced directives, preference for treatment plan, and
periodic re-evaluation of preference and treatment goals; 6)
resources are provided that support an integrated model of
HF palliative care [44].
A transitional care model embracing the preceding six
principles will be adopted to guide the intervention
design of this study. This study took reference of the
transitional care model structure built by Naylor [45]
and Coleman [46], which includes interfacing the pre-
discharge phase with the post-discharge phase, contin-
ued with planned, proactive, and sustained follow-up for
the post-discharged patients [42]. The design of the tran-
sitional care model in this study shares the essence of
transitional care proposed by Naylor and Coleman to
ensure post-discharge healthcare continuity and to avoid
preventable readmissions [39, 45–47] but differs in the con-
tent by introducing the principles of HF palliative care as
mentioned above. The key features in the transitional
model of care to be used in this study are known as the
four Cs, and were proposed by Wong et al. [42, 43, 48–50].
The four Cs refer to comprehensiveness, continuity, coord-
ination, and collaboration. Being comprehensive means that
the multidisciplinary team, together with the case manager,
will conduct a holistic assessment of a patient’s condition
and assume responsibility for anticipating the patient’s
needs and facilitating the transition to home. Continuity of
care is ensured by timely, proactive, and sustained follow-
up on a regular basis. Coordination refers to the nurse case
manager facilitating the communication with physicians,
social workers, and other healthcare team members to
respond to patients’ needs when necessary. Collaboration
occurs not only among healthcare team members, but also
between the provider and the patient/family. The patient/
family needs to be involved as a partner, an active agent of
care [42, 50].
Study settings and participants
This is a multisite study conducted in collaboration with
the palliative care teams from three regional hospitals.
In-hospital patients with ESHF are reviewed by the phy-
sicians, and patients who are seen to be not benefiting
from active medical treatment are considered for pallia-
tive care. The general inclusion criteria for subject re-
cruitment include the ability to speak Cantonese, living
within the hospital service area, and the ability to be
contacted by phone. Specific inclusion criteria are based
on the National Gold Standards Framework, Prognostic
Indicator Guidance 2008 [51], in which patients must
fulfill at least two of the indicators: (i) HF with New
York Heart Association stage III or IV, (ii) patient
thought to be in the last year of life, (iii) repeated hos-
pital admissions with symptoms of HF, (iv) existence of
physical or psychological symptoms despite optimal
therapy. The nurse who is responsible for recruitment
identifies eligible subjects, and the physician confirms
that the patient fulfills the specific criteria and refers
him/her to the PC team. Those with cognitive impair-
ment, diagnosed with severe psychiatric disorders in
their medical record, or discharged to a nursing home or
other institution are excluded.
Recruitment procedures
The ESHF patients who fulfill the set criteria are placed
on the palliative care pathway. The research team ap-
proaches the patients for subject recruitment. A written
consent form is signed if patients agree to participate in
the study. After obtaining written informed consent, a
research assistant who is blinded to the treatment as-
signment conducts a baseline interview, including partic-
ipants’ demographic data. The self-rated measures
adopted in this study are detailed in the outcome mea-
sures section below.
Randomization and blinding
Randomization in permuted blocks is used. The per-
muted block randomization scheme was generated by
computer software at www.randomization.com [52].
Randomization is done by an independent research team
member who is not involved in any other parts of the
study, in order to guarantee allocation concealment. The
group assignment is placed in a sealed envelope, which
is retained by the site investigator, who has no connec-
tion with the clinical team. Having successfully recruited
a subject, the research nurse calls the independent site
investigator to open an envelope and assign a group
code to the participant according to the randomization
scheme. The independent site investigator is blinded to
the meaning of the group code. The participants and
family members need to be introduced to the interven-
tion program and they are not blinded. The intervention
nurses are also not blinded since they need to deliver
the intervention. Only the research assistants who help
to collect the data are blinded to the group assignment.
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Study intervention
Usual care
Participants in both groups receive customary hospital-
based care, which is a palliative care consultation ser-
vice. The service includes communication on diagnosis,
prognosis, advance care planning, symptom assessment,
and caregiver support by a palliative physician or nurse.
Home visits and telephone calls may be provided as part
of the customary service if deemed necessary, and the
number of visits and calls provided will be recorded for
reference in the final analysis.
Usual care plus HPHP
In this group, the Home-based Palliative HF Program
(HPHP) is initiated and supported by a core multidiscip-
linary palliative care team. The composition of the core
team includes a palliative care nurse who acts as a nurse
case manager (NCM), a palliative specialist, a social
worker, and a group of trained nursing students as vol-
unteers. The effect of using volunteers adds value, as
shown in a local study [42] and elsewhere [53, 54]. The
HPHP was developed based on the six principles for pal-
liative care and the four-Cs transitional model, and as
described in the conceptual framework section. Struc-
tured and regular home visits and telephone calls are
two common approaches that can bring about positive
effects in transitional care [23, 42, 50, 55, 56]. The com-
prehensive package of care will be guided by evidence-
driven protocols formulated by the research team.
Below are the descriptions of the protocols.
1. Protocol for home visits – The first visit will be
jointly delivered by the NCM and nursing students.
Subsequent monthly visits will be conducted by the
NCM or nursing students separately. The NCM will
follow up on the health problems identified in the
pre-discharge assessment in the first home visit. The
subsequent home visits will follow up on the issues
and goals of the previous visit. The nursing students
will focus on social issues and report to the NCM
and social worker after each home visit. The NCM
will help set mutual goals with the patient to en-
hance optimal symptom control as well as social,
psychological, and spiritual well-being. The NCM
will consult the physicians in palliative care for clin-
ical decisions, if needed. All home visits will be doc-
umented on structured forms designed based on the
Omaha System [57]. The Omaha System was origin-
ally used in the United States. In Hong Kong, the re-
search team has used it and found it comprehensive
and valid for use with community-dwelling patients,
including medical and hospice groups [29, 42, 49].
2. Protocol for telephone follow-up – The NCM will
initiate calls between home visits to monitor
progress, provide health advice, reinforce appropri-
ate health behavior, assess the need for referral, and
review management goals with the patients. The
Omaha System will continue to be used as a frame-
work to guide practice and documentation.
3. Protocol for referral system – A referral protocol will
be established in case patients’ needs require further
help, including: (a) social services – social,
psychological, and financial support; (b) pastoral
service – spiritual support; (c) medical clinic – medical
review, drug adjustment; (d) nurse clinic – health
assessment, non-pharmacological measures of symp-
tom control; (e) emergency room – urgent conditions.
4. Protocol for patient-initiated calls – Besides
provider-initiated home visits and telephone calls,
patients can initiate calls to the NCM if they require
advice and seek help before the next structured ac-
tivity. The NCM will manage the calls according to
the telephone follow-up and referral protocols. The
content and duration of the calls will be
documented.
Training program for nurse case managers and
volunteers
Training nurse case managers
The NCMs already have 6 years of clinical experience in
palliative and/or HF care and have completed the post-
registration specialty course. They have participated in a
training program to enable them to master the key ele-
ments of the HPHP and enhance their relevant know-
ledge and skills (see Additional file 2). The training
program was delivered by the research team in partner-
ship with experienced clinical experts.
Training volunteers
Volunteers are final year nursing students from a local
nursing school, who have completed a 9-hour training
program including theory- and practice-based content




Before the patient is discharged, the NCM will conduct
a pre-discharge interview with the patient and family.
The NCM will discuss the patient’s current physical, psy-
chological, social, and spiritual status with the patient
and family, as well as their preferred care approach. The
patient and family will be encouraged to ask questions
and to express their views throughout the process. At
the end of the interview, the NCM will convene to de-
velop a care plan in accordance with the wishes of the
patient and family. Upon patient discharge, the nurse
will meet with the patient and family to explain the
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HPHP arrangements and to document the assessment
and plan using the Omaha System, which encompasses a
comprehensive assessment, intervention, and evaluation
scheme [57].
Post-discharge phase
The first month post-discharge will include weekly care
support: week 1 - the NCM and nursing students con-
duct a home visit together; week 2 - the NCM makes a
telephone follow-up call; week 3 - the nursing students
conduct a home visit in pairs; week 4 - the NCM makes
a telephone follow-up call.
Second and subsequent months post-discharge
The NCM will provide a monthly home visit, supple-
mented by a social visit and a telephone follow-up by
nursing students each month. The patient will receive
the HPHP for up to 12 months.
Outcome measures
Data for the outcome measures will be collected at five
time points: at discharge and at 1, 3, 6, and 12 months
post-discharge. A research assistant with no clinical
association with the patients will be responsible for
collecting the data. In order to ensure the quality of the
data collected, the research assistant will be trained in
using different data collection tools. A value of 10 %
will be used to test the intra-rater reliability, which in-
volves the assistant collecting the same set of data twice
within a short interval of time. All the data is independ-
ently checked by a member not involved in data collec-
tion to ensure the quality of the data collected. All data
will be stored in a locked cabinet and will be entered in
encrypted files to ensure data protection.
Primary outcome
The primary outcome is quality of life, which will be mea-
sured by an HF-specific scale, the Chronic Heart Failure
Questionnaire - Chinese version (CHQ) at 4 weeks post-
discharge. The CHQ is one of the most commonly used
HF-specific QOL instruments. It was developed by Guyatt
et al. [58] in Canada. The tool has 20 items on a 7-point
Likert scale measuring four domains: dyspnea, fatigue,
emotional status, and mastery. The CHQ has been trans-
lated into Chinese and validated [59]. The internal
consistency and test-retest reliability are good, with a
Cronbach’s alpha of 0.95 and an intra-class correlation
coefficient (ICC) of 0.75 [59]. In addition, the quality of
life will also be measured by the McGill Quality of Life
Questionnaire - Hong Kong version (MQOL-HK),
which is a palliative-specific instrument measuring four
domains: physical, psychological, existential, and
support on a numerical scale from 0 to 10. It has been
validated among palliative patients in Hong Kong with
good reliability (the ICC is 0.85 (p < 0.0001) and the
Cronbach’s alpha is 0.83) [60].
Secondary outcomes
Evaluated health outcomes will be functional status,
symptom intensity, and satisfaction with care. Functional
status will be measured by the Palliative Performance
Scale (PPS). The PPS, developed by Anderson et al. [61]
based on the Karnofsky Performance Scale, is a tool spe-
cifically designed for palliative patients that reflects the
changing physical condition in five aspects: ambulation,
activities/evidence of disease, self-care, intake, and level
of consciousness. The PPS is a clinical tool commonly
used in local settings. The level of physical performance
is rated on a scale of 100 (normal) to 0 (death), mea-
sured in 10 % decrement levels. The scale has been
validated and the inter-rater reliability between doctors
and nurses was maintained at .85 with strong kappa
values of .97 [62]. The internal consistency is also good,
with a Cronbach’s alpha equal to 0.83 [63].
The symptom intensity will be measured by the
Edmonton Symptom Assessment System (ESAS). The
ESAS assesses nine symptoms: pain, fatigue, nausea,
depression, anxiety, drowsiness, appetite, sensation of
well-being, and dyspnea, measured on a 0–100 mm
visual analog scale (VAS). One extra empty VAS is left
for the assessment of a less frequent symptom that may
be important for an individual patient. The ESAS is
widely adopted locally, and has been found to be a valid,
reliable instrument for use among palliative care patients
[64, 65]. A local study has also shown that the ESAS can
help quantify symptoms and is an independent prognos-
ticator for survival [66].
Satisfaction with care will be measured by the 15-item
questionnaire used in the study of Wong et al., with
validity confirmed by an expert panel and a reported
test-retest reliability of .87 [42].
The service utilization outcome is measured by the
hospital readmission rate, length of stay, and emergency




We estimated the sample size based on the study by
Brannstrom and Boman [67], which detected a significant
improvement in quality of life (intervention 60.4 versus
control 52.3) after the structured palliative home care
intervention provided by a multidisciplinary team among
heart failure patients. A sample size of 117 for each arm is
required to achieve a power of 80 % at a significance level
of 0.05. To account for a 20 % attrition rate, 140 subjects
for each arm with a total of 280 subjects are needed.
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Data analysis
We will use SPSS 22.0 for Windows to perform a statis-
tical analysis. Descriptive statistics and means will be used
to describe the participants’ background information and
clinical variables. Poisson regression will be used to exam-
ine the mean difference for the hospital readmission rate
between groups. A generalized estimating equation (GEE)
will be used to examine the group, time, and interaction
effects on the secondary outcome variables. The GEE is
chosen because it treats observations of longitudinal data
as correlated and thus is more robust in estimating stand-
ard errors [68].
The final report will follow the Consolidated Standards
of Reporting Trials (CONSORT) statement as well as its
extension for non-pharmacological interventions/com-
plex intervention.
Ethical considerations
This study has been reviewed and approved by the Re-
search Ethics Committees of the two clusters in which the
three hospitals are situated, the Institutional Review Board
of the University of Hong Kong/Hospital Authority Hong
Kong West Cluster, and the Kowloon Central/Kowloon
East Cluster Research Ethics Committee (HKU/HA HKW
IRB UW12-202; KC/KE120062/ER2), as well as by the
Human Subjects Ethics Sub-Committee of the Hong Kong
Polytechnic University (HSEARS20111003010).
Discussion
Although there is evidence that successful transitional
care interventions are effective in reducing readmission
rates [46, 47, 69], the subjects in previous studies were
chronically ill or elderly persons and there was no pallia-
tive care element involved. A recent systematic review
conducted to examine the effect of transitional care inter-
ventions in preventing readmission for patients with heart
failure revealed that patients with end-stage cardiovascular
diseases were commonly not included in the trial; there-
fore, the results may not be applicable to the severely ill
population [23]. Although randomized controlled trials of
home-based programs had previously been conducted on
severely ill patients [4, 70, 71], the interventions were initi-
ated by health maintenance organizations [4, 70] and in
an outpatient setting [71], while the intervention in our
study begins in the in-patient hospital setting, aiming to
ensure continuity of care in the hospital-to-home inter-
face. In addition, Hansen and his colleagues [72] have
evaluated interventions to reduce readmission within
30 days of hospital discharge, concluding that they did not
identify distinct interventions or multicomponent
discharge bundles that appeared to reliably decrease hos-
pital readmission rates. Recent studies examined the im-
pact of palliative care interventions on readmission rates
and found that palliative care post-discharge could reduce
30-day hospital readmissions among seriously ill patients
[73, 74]. However, these were retrospective studies. Other
palliative care interventions were targeted at a group with
late-stage diseases including cancer, chronic obstructive
pulmonary disease (COPD), and end-stage renal disease
[75, 76], but did not test any patients from the end-stage
heart failure population. Few randomized controlled trials
have been conducted to inform practitioners which
models work best for end-stage HF patients under pallia-
tive care. In one of them, Brumley [4] compared the ef-
fects of usual care with a home-based palliative care
intervention delivered by an interdisciplinary team to a
group of terminal patients with HF, COPD, and cancer,
reporting that those enrolled in palliative care made sig-
nificantly less use of the emergency department (palliative
20 % versus usual care 33 %) and hospitalization (palliative
36 % versus usual care 59 %), resulting in an average 45 %
decrease in costs as compared to patients under usual
care. Outcome measures other than service use and the
cost of the effects of palliative care have been reported.
Morrison [77] translated the palliative care service into
costs and found that the palliative group experienced sig-
nificant reductions in costs involving admissions, labora-
tory tests, pharmacy services, and intensive care services
compared to the usual care group.
The value of this study is threefold: to the healthcare
system, to the patients, and to the science of healthcare
research. If the HPHP proves successful, it could help
reduce the burden on over-taxed hospital services by
building a transitional care model that gradually shifts
care from the hospital to the community. The second
benefit of this project is for patients. The HPHP aims
at helping patients with end-stage HF to control symp-
toms and maintain quality of life using a home-based
care model. The patients can then remain in an envir-
onment that is familiar to them, receiving support from
the healthcare team after hospital discharge. The third
aspect of value is the contribution of this study to the
science of healthcare research. Conventional end-of-life
research tends to focus on single aspects, such as ad-
vanced directives, and targets mainly the cancer group.
This study is an original effort to design a multidiscip-
linary transitional care model for end-stage HF patients
and to subject it to scientific testing using a random-
ized controlled trial. The results of this study will help
to inform practitioners and policy makers in planning
and developing effective models that will fill the service
gap and enhance quality of care for non-cancer patients
at the end of life.
Trial status
This study is currently at the final stage of data
collection.
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